440 related articles for article (PubMed ID: 15849742)
1. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells.
Vayssade M; Haddada H; Faridoni-Laurens L; Tourpin S; Valent A; Bénard J; Ahomadegbe JC
Int J Cancer; 2005 Oct; 116(6):860-9. PubMed ID: 15849742
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53-family members and associated target molecules in breast cancer cell lines in response to vincristine treatment.
Vayssade M; Faridoni-Laurens L; Bénard J; Ahomadegbe JC
Biochem Pharmacol; 2002 May; 63(9):1609-17. PubMed ID: 12007564
[TBL] [Abstract][Full Text] [Related]
3. One, two, three--p53, p63, p73 and chemosensitivity.
Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of p63 and p73 expression.
Waltermann A; Kartasheva NN; Dobbelstein M
Oncogene; 2003 Aug; 22(36):5686-93. PubMed ID: 12944917
[TBL] [Abstract][Full Text] [Related]
5. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
Muttray AF; Cox RL; Reinisch CL; Baldwin SA
Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
[TBL] [Abstract][Full Text] [Related]
6. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
[TBL] [Abstract][Full Text] [Related]
7. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
[TBL] [Abstract][Full Text] [Related]
8. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
Venkatanarayan A; Raulji P; Norton W; Chakravarti D; Coarfa C; Su X; Sandur SK; Ramirez MS; Lee J; Kingsley CV; Sananikone EF; Rajapakshe K; Naff K; Parker-Thornburg J; Bankson JA; Tsai KY; Gunaratne PH; Flores ER
Nature; 2015 Jan; 517(7536):626-30. PubMed ID: 25409149
[TBL] [Abstract][Full Text] [Related]
9. p63 and p73: roles in development and tumor formation.
Moll UM; Slade N
Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
[TBL] [Abstract][Full Text] [Related]
10. P53-independent downregulation of p73 in human cancer cells treated with Adriamycin.
Yuan R; Meng Q; Hu H; Goldberg ID; Rosen EM; Fan S
Cancer Chemother Pharmacol; 2001; 47(2):161-9. PubMed ID: 11269743
[TBL] [Abstract][Full Text] [Related]
11. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
[TBL] [Abstract][Full Text] [Related]
12. Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity.
Ozaki T; Sugimoto H; Nakamura M; Hiraoka K; Yoda H; Sang M; Fujiwara K; Nagase H
FEBS J; 2015 Jan; 282(1):114-28. PubMed ID: 25331851
[TBL] [Abstract][Full Text] [Related]
13. E1A activates transcription of p73 and Noxa to induce apoptosis.
Flinterman M; Guelen L; Ezzati-Nik S; Killick R; Melino G; Tominaga K; Mymryk JS; Gäken J; Tavassoli M
J Biol Chem; 2005 Feb; 280(7):5945-59. PubMed ID: 15572378
[TBL] [Abstract][Full Text] [Related]
14. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
[TBL] [Abstract][Full Text] [Related]
15. Alterations of p63 and p73 in human cancers.
Inoue K; Fry EA
Subcell Biochem; 2014; 85():17-40. PubMed ID: 25201187
[TBL] [Abstract][Full Text] [Related]
16. p73, a sophisticated p53 family member in the cancer world.
Ozaki T; Nakagawara A
Cancer Sci; 2005 Nov; 96(11):729-37. PubMed ID: 16271066
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
[TBL] [Abstract][Full Text] [Related]
18. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Venkatanarayan A; Raulji P; Norton W; Flores ER
Cell Cycle; 2016; 15(2):164-71. PubMed ID: 26652033
[TBL] [Abstract][Full Text] [Related]
20. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest.
Vossio S; Palescandolo E; Pediconi N; Moretti F; Balsano C; Levrero M; Costanzo A
Oncogene; 2002 May; 21(23):3796-803. PubMed ID: 12032848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
